Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE-T
NL-OMON56084Phase 3Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Thalassaemia, beta thalassemia, alpha thalassemia and 2 more comparing Mitapivat with Placebo (2 arms). Primary endpoint: Transfusion reduction response. Started Jun 2022; status: recruiting.
02
Drugs
mitapivat
03
Conditions
Thalassaemiabeta thalassemiaalpha thalassemiaalpha-thalassemia intermediahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on NL-OMON56084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56084.